Lyell Immunopharma misses Q4 revenue estimates

Lyell Immunopharma

12/03/2026 21:12

Overview

CAR T-cell therapy developer's Q4 revenue missed analyst expectations

Adjusted net loss for Q4 was narrower than expected, beating analyst estimates

Company closed $50 mln equity tranche after achieving clinical milestone for ronde-cel

Outlook

Company expects current cash to fund operations into Q2 2027 through multiple clinical milestones

Result Drivers

Cash, cash equivalents and marketable securities as of December 31, 2025 were approximately $247.2 million

ACQUISITION-RELATED EXPENSES - Q4 net loss included $66.3 mln in acquired in-process R&D expense and $19.7 mln in stock-based compensation tied to LYL273 license acquisition

COST REDUCTIONS - Lower personnel and facility costs following workforce reduction and technology transfer of ronde-cel partially offset higher R&D expenses

Company press release: ID:nGNX7rqRn7

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$6,000
$12,200 (5 Analysts)
Q4 Adjusted Net Income
Beat
-$33.06 mln
-$47.67 mln (4 Analysts)
Q4 Net Income
-$140.72 mln
Q4 Operating Expenses
$127.65 mln
Q4 Operating Income
-$127.64 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Lyell Immunopharma Inc is $34.00, about 35.2% above its March 11 closing price of $25.14

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)